Did you know that your browser is out of date?
For the best experience we recommend upgrading to the latest version of these supported browsers:
I wish to continue viewing on my unsupported browser
For the best experience we recommend upgrading to the latest version of these supported browsers:
I wish to continue viewing on my unsupported browser
Email: david.blackburn@nera.com
vCard: Download
PhD in economics, Harvard University
ScB in applied mathematics and economics, with Honors, Brown University
Dr. Blackburn is a Director and Head of the Life Sciences Group. Dr. Blackburn's areas of expertise include intellectual property (IP), antitrust and competition policy, and econometric analysis. In his IP practice, he conducts research and prepares expert reports for patent, trademark, and copyright infringement disputes, and false and misleading advertising cases. Dr. Blackburn regularly conducts analyses related to the issues of commercial success and preliminary and permanent injunctions in both Inter Partes Review and Abbreviated New Drug Application (ANDA) proceedings pursuant to the Hatch-Waxman Act.
In his antitrust and commercial damages practices, he has assessed liability and damages in disputes related to tying, price discrimination, monopolization, and breaches of contract, among others. He has also assessed the competitive effects of mergers and acquisitions, as well as issues relating to impact and damages in class action litigation. Dr. Blackburn has written and spoken publicly on a number of these issues.
In both his antitrust and IP practices, Dr. Blackburn has experience critiquing damage models, and designing and providing economic analysis. In recent years, his work has included merger analyses and royalty rate setting hearings involving high-profile clients in the music and entertainment industry. His experience covers a variety of other industries as well, including computer software, medical devices, pharmaceuticals, natural resources, industrial goods and chemicals, consumer products, and financial services.
Before joining NERA, Dr. Blackburn received his PhD in economics from Harvard University and his ScB in applied mathematics and economics, with honors, from Brown University. While at Harvard, his research focused on the economics of IP and the development of monetary systems. Dr. Blackburn's doctoral dissertation was an analysis of the economics of copying, with a detailed examination of the effects of file sharing on the recorded music industry. His research was cited in testimony to the US Senate by the chairman and CEO of the Recording Industry Association of America in MGM v. Grokster.
Dr. Blackburn has taught undergraduate-level courses at Harvard University and Framingham State College, and a graduate-level course in the economics of regulation and antitrust at the Universidad Nacional de Tucumán in Argentina.
Spanish
Title | Type | Author | ||
---|---|---|---|---|
Glossary of Pharmaceutical Terms and Acronyms | White Paper | Dr. David Blackburn and Dr. Chris Stomberg | ||
Expert Witnesses in Competition Disputes | Published Article | By Dr. David Blackburn, Nathan Blalock, Dr. Subbu Ramanarayanan, and Dr. Paul Wong | ||
25 Percent, 50 Percent ... What is in a Number? | Presentation | By Dr. David Blackburn | ||
25 Percent, 50 Percent...What's In A Number? | Published Article | By Dr. Christine Siegwarth Meyer and Dr. David Blackburn | ||
The 25 Percent Rule in Patent Damages: Dead and Now Buried | Working Paper | By Dr. David Blackburn et al. | ||
Words Matter: Economics & A Literal Reading of Mars, American Seating, and Monsanto-R... | Working Paper | By Dr. David Blackburn | ||
Reasonable Royalties After eBay | Published Article | By Dr. Christine Siegwarth Meyer and Dr. David Blackburn | ||
Where's the Economics Behind Lucent v. Gateway et al.? | Working Paper | By Dr. David Blackburn et al. | ||
|
Title | Date | |||
---|---|---|---|---|
NERA Insights Webinar Series: Intellectual Property | 19 November 2020 | |||
Economic Trends in Pharma | 30 October 2020 | |||
2nd Annual GCR Live: Pharmaceuticals | 27 February 2020 | |||
NERA Insights Webinar | What’s a Reasonable Opinion for a Reasonable Royalty? | 20 February 2020 | |||
The Economics of Biosimilars: Market Access, Pricing and Legal Considerations | 10 December 2019 | |||
Two NERA Experts speak at Summit on Biosimilars | 24 June 2019 | |||
Patent Settlement Agreements: Impacts on Antitrust Enforcement | 27 May 2016 | |||
IP Life Sciences Exchange | 10 November 2015 | |||
European Antitrust Enforcement for Pay-For-Delay Settlements | 10 September 2015 | |||
Calculating & Proving Patent Damages Conference | 18 September 2014 | |||
Title | Date | Type | ||
---|---|---|---|---|
David Blackburn Quoted in "Comparing the Economics of Biosimilars and Generics" | 27 June 2019 | Media Coverage | ||
NERA Economic Consulting Announces Officer-Level Promotions | 06 September 2012 | Press Release | ||
|